EUVIMEDEUVIMED entdecken
Crossref

VenusP‐Valve: Outcomes Beyond 5 Years

Reem Rashed iD, Matthew I Jones, Pimpak Prachasilchai, Sophia S F Yong, Worakan Promphan, Eric Rosenthal, Shakeel A Qureshi

Catheterization and Cardiovascular Interventions · 2026-03 · 107 (4) · 1237-1245

DOI: 10.1002/ccd.70457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 08.01.2026. Verfasst von Reem Rashed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Congenital Cardiology, Evelina London Children's Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Heart Valve Prosthesis Implantation, Cardiac Catheterization, Pulmonary Valve Insufficiency, Heart Valve Prosthesis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Percutaneous pulmonary valve implantation (PPVI) is an alternative to surgery for dysfunctional right ventricular outflow tracts (RVOTs). The VenusP‐valve is a self‐expanding transcatheter valve, available in diameters from 24 to 36 mm, and is designed for use in the larger RVOTs.

Aims

A retrospective review to evaluate the medium to long‐term results of the VenusP‐valve, focusing on patient outcomes and durability of the valve.

Methods

Between October 2013 and September 2018, 58 patients with severe pulmonary regurgitation (PR) underwent attempted PPVI with the VenusP‐valve at Evelina London Children's Hospital, London, UK, and Pediatric Heart Center, Queen Sirikit National Institute of Child Health, Bangkok, Thailand. Data on patient characteristics, clinical and imaging outcomes, and follow‐up status were collected retrospectively.

Results

During the studied period, 56 (96.6%) patients had a successful PPVI out of 58 attempted procedures. One attempt was unsuccessful, and one patient experienced valve migration, both requiring surgical intervention. There were no early or late deaths, and no patients developed valve stenosis or severe PR. Additionally, none of the patients experienced infective endocarditis or significant ventricular arrhythmias. Fluoroscopic evaluation at 6–12 months revealed wire frame fractures in 13 patients (23.2%), typically in the proximal flare of the valve; however, these fractures did not affect the valve function. Atrial arrhythmias occurred in two patients (3.5%), one of whom was managed medically and the other underwent successful ablation. The cohort of patients showed a significant decrease in PR on transthoracic echocardiography and a significant reduction in indexed right ventricular end‐diastolic volumes and pulmonary regurgitant fraction by cardiac magnetic resonance imaging at between 6 and 12 months. These results were sustained on serial follow‐up.

Conclusion

VenusP‐valve implantation is associated with excellent early and mid‐term outcomes over a 5−10 year period, with no major complications related to valve function. However, longer‐term follow‐up is required to further assess its performance and longevity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve Prosthesis ImplantationCardiac CatheterizationPulmonary Valve InsufficiencyHeart Valve ProsthesisPulmonary ValveHumansRetrospective StudiesTreatment OutcomeFemaleProsthesis DesignTime FactorsRecovery of FunctionMaleVentricular Function, RightChild, PreschoolInfantRisk FactorsSeverity of Illness IndexChildHemodynamicsAdolescent

Stichwörter der Autor:innen

percutaneous pulmonary valve implantation (PPVI)pulmonary regurgitation (PR)pulmonary valve replacement (PVR)right ventricular outflow tract (RVOT) dysfunction

Autor:innen und Institutionen

  • Department of Congenital Cardiology, Evelina London Children's Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
  • Department of Cardiology, Tanta University Hospital, Tanta, Egypt.
  • Department of Paediatric Cardiology, Pediatric Heart Center, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University, Bangkok, Thailand.

ORCID-Profile: Reem Rashed

Zitieren

APA

Rashed, R., Jones, M. I., Prachasilchai, P., Yong, S. S. F., Promphan, W., Rosenthal, E., & Qureshi, S. A. (2026). VenusP‐Valve: Outcomes Beyond 5 Years. Catheterization and Cardiovascular Interventions, 107(4), 1237-1245. https://doi.org/10.1002/ccd.70457

Vancouver

Rashed R, Jones MI, Prachasilchai P, Yong SSF, Promphan W, Rosenthal E, et al. VenusP‐Valve: Outcomes Beyond 5 Years. Catheterization and Cardiovascular Interventions. 2026;107(4):1237-1245. doi:10.1002/ccd.70457

BibTeX
@article{Rashed2026,
  author = {Rashed, Reem and Jones, Matthew I and Prachasilchai, Pimpak and Yong, Sophia S F and Promphan, Worakan and Rosenthal, Eric and Qureshi, Shakeel A},
  title = {VenusP‐Valve: Outcomes Beyond 5 Years},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  volume = {107},
  number = {4},
  pages = {1237--1245},
  doi = {10.1002/ccd.70457}
}
Kostenlos starten →